Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Egorin

Showing results (51-60 of 159) with videos related to

Pageof 16
Sort By:
Archives of Dermatology|April 1, 1989
Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentationT D Horn, R A Beveridge, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusionsB A Conley, M J Egorin, E G Zuhowski, et al.
Cancer Research|February 1, 1994
Cellular pharmacology of N1- and N8-aziridinyl analogues of spermidineZ M Yuan, M J Egorin, D M Rosen, et al.
Cancer Treatment Reports|June 1, 1986
Phase I trial of menogaril administered as an intermittent daily infusion for 5 daysL M Sigman, D A Van Echo, M J Egorin, et al.
Cancer Research|July 1, 1988
Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamideS W Snyder, M J Egorin, L A Geelhaar, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|March 23, 2007
Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milkM A Russell, M W Carpenter, M S Akhtar, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugsD L de Valeriola, D D Ross, A Forrest, et al.
Kidney International|August 1, 1991
Protective action of glycine in cisplatin nephrotoxicityS N Heyman, S Rosen, P Silva, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 1983
The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986)J F Spiegel, M J Egorin, J M Collins, et al.
Cancer Communications|January 1, 1990
Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexaneS W Snyder, M J Egorin, E G Zuhowski, et al.
Pageof 16

Showing results (51-60 of 159) with videos related to

Sort By:
Pageof 16
Archives of Dermatology|April 1, 1989
Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentationT D Horn, R A Beveridge, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusionsB A Conley, M J Egorin, E G Zuhowski, et al.
Cancer Research|February 1, 1994
Cellular pharmacology of N1- and N8-aziridinyl analogues of spermidineZ M Yuan, M J Egorin, D M Rosen, et al.
Cancer Treatment Reports|June 1, 1986
Phase I trial of menogaril administered as an intermittent daily infusion for 5 daysL M Sigman, D A Van Echo, M J Egorin, et al.
Cancer Research|July 1, 1988
Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamideS W Snyder, M J Egorin, L A Geelhaar, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|March 23, 2007
Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milkM A Russell, M W Carpenter, M S Akhtar, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugsD L de Valeriola, D D Ross, A Forrest, et al.
Kidney International|August 1, 1991
Protective action of glycine in cisplatin nephrotoxicityS N Heyman, S Rosen, P Silva, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 1983
The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986)J F Spiegel, M J Egorin, J M Collins, et al.
Cancer Communications|January 1, 1990
Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexaneS W Snyder, M J Egorin, E G Zuhowski, et al.
Pageof 16